CoChat

Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatment

Laird, Veronika R., Plucinski, Mateusz M., Venkatesan, Meera, Rondini, Kelsey A., Randrianarivelojosia, Milijaona, Andriamananjara, Mauricette N., Moonga, Hawela, Ishengoma, Deus S., Chidimatembue, Arlindo, Dimbu, Pedro Rafael, Adeothy, Adicatou-Laï, Beavogui, Abdoul Habib, Kariuki, Simon, Nsobya, Sam L., Uwimana, Aline, Kahunu, Gauthier Mesia, Assefa, Ashenafi, Koita, Ousmane A., Lucchi, Naomi W., Souza, Samaly S. Svigel, Zhou, Zhiyong, Moriarty, Leah F., Halsey, Eric S. · 2025 · Malaria Journal
Cited by 13

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12936-025-05248-2

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 59

  1. WHO. World malaria report 2023. Geneva: World Health Organization; 2023.
  2. Rosenthal PJ, Asua V, Conrad MD. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nat Rev Microbiol. 2024;22:373–84. · DOI · Paper page
  3. van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952–61. · DOI · Paper page
  4. Gansané A, Moriarty LF, Ménard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018. Malar J. 2021;20:48. · DOI
  5. Moriarty LF, Nkoli PM, Likwela JL, Mulopo PM, Sompwe EM, Rika JM, et al. Therapeutic efficacy of artemisinin-based combination therapies in Democratic Republic of the Congo and investigation of molecular markers of antimalarial resistance. Am J Trop Med Hyg. 2021;105:1067–75. · DOI
  6. Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J. 2021;20:484. · DOI
  7. Laury JE, Mugittu K, Kajeguka DC, Kamugisha E, Ishengoma DS, Mandara CI, et al. Efficacy and safety of artemether-lumefantrine against uncomplicated falciparum malaria infection in Tanzania, 2022: a Single-Arm Clinical Trial. J Infect Dis. 2024. https://doi.org/10.1093/infdis/jiae425. · doi:10.1093/infdis/jiae425
  8. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, et al. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis. 2013;207:842–7. · DOI
  9. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833–43. · DOI · Paper page
  10. Otienoburu SD, Maïga-Ascofaré O, Schramm B, Jullien V, Jones JJ, Zolia YM, et al. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate–amodiaquine fixed dose combination or artemether–lumefantrine in Liberia. Malar J. 2016;15:452. · doi:10.1186/s12936-016-1503-3
  11. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A, et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health. 2007;12:736–42. · DOI · Paper page
  12. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, et al. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg. 2006;75:155–61. · doi:10.4269/ajtmh.2006.75.155
  13. Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis. 2011;204:1120–4. · DOI
  14. Maiga H, Grivoyannis A, Sagara I, Traore K, Traore OB, Tolo Y, et al. Selection of pfcrt K76 and pfmdr1 N86 coding alleles after uncomplicated malaria treatment by artemether-lumefantrine in Mali. Int J Mol Sci. 2021;22:6057. · doi:10.3390/ijms22116057
  15. White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malar J. 2008;7:9. · DOI · Paper page
  16. Price RN, Uhlemann A-C, van Vugt M, Brockman A, Hutagalung R, Nair S, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis. 2006;42:1570–7. · DOI · Paper page
  17. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J. 2009;8:11. · DOI · Paper page
  18. Halsey ES, Venkatesan M, Plucinski MM, Talundzic E, Lucchi NW, Zhou Z, et al. Capacity development through the US President’s Malaria Initiative–supported antimalarial resistance monitoring in Africa network. Emerg Infect Dis. 2017;23:S53–6. · DOI · Paper page
  19. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
  20. Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V. Robust algorithm for systematic classification of malaria late treatment failures as recrudescence or reinfection using microsatellite genotyping. Antimicrob Agents Chemother. 2015;59:6096–100. · DOI
  21. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, Rosenthal PJ, et al. Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg. 2006;75:836–42. · DOI · Paper page
  22. Sondo P, Derra K, Nakanabo SD, Tarnagda Z, Kazienga A, Zampa O, et al. Artesunate-amodiaquine and artemether-lumefantrine therapies and selection of pfcrt and pfmdr1 alleles in Nanoro, Burkina Faso. PLoS ONE. 2016;11: e0151565. · DOI
  23. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis. 2014;210:344–53. · DOI
  24. Dettori JR, Norvell DC, Chapman JR. Fixed-effect vs random-effects models for meta-analysis: 3 points to consider. Glob Spine J. 2022;12:1624. · DOI · Paper page
  25. Ochong EO, van den Broek IVF, Keus K, Nzila A. Association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg. 2003;69:184–7. · DOI
  26. Tinto H, Guekoun L, Zongo I, Guiguemdé RT, D’Alessandro U, Ouédraogo JB. Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso. Trop Med Int Health. 2008;13:238–40. · doi:10.1111/j.1365-3156.2007.01995.x
  27. Picot S, Olliaro P, de Monbrison F, Bienvenu A-L, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J. 2009;8:89. · DOI · Paper page
  28. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Björkman A. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol. 2006;6:309–14. · doi:10.1016/j.meegid.2005.09.001
  29. Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg. 2008;78:455–61. · DOI
  30. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, et al. Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology. 1997;114(Pt 3):205–11. · DOI
  31. Taylor SM, Juliano JJ. Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot. J Infect Dis. 2014;210:335–7. · DOI
  32. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJM, Mutabingwa TK, Sutherland CJ, et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother. 2007;51:991–7. · DOI · Paper page
  33. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005;191:1014–7. · DOI · Paper page
  34. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother. 2006;50:1893–5. · DOI
  35. Somé AF, Séré YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine- sulfadoxine-pyrimethamine but not dihydroartemisinin- piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2010;54:1949–54. · DOI
  36. Gadalla NB, Adam I, Elzaki S-E, Bashir S, Mukhtar I, Oguike M, et al. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother. 2011;55:5408–11. · DOI
  37. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O’Neil M, et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2009;53:888–95. · doi:10.1128/aac.00968-08
  38. Lekana-Douki JB, Dinzouna Boutamba SD, Zatra R, Zang Edou SE, Ekomy H, Bisvigou U, et al. Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine. Infect Genet Evol. 2011;11:512–7. · DOI
  39. Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK, et al. In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2015;59:734–7. · DOI
  40. Zhou Z, Gimnig JE, Sergent SB, Liu Y, Abong’o B, Otieno K, et al. Temporal trends in molecular markers of drug resistance in Plasmodium falciparum in human blood and profiles of corresponding resistant markers in mosquito oocysts in Asembo, western Kenya. Malar J. 2022;21:265. · DOI
  41. Folarin OA, Bustamante C, Gbotosho GO, Sowunmi A, Zalis MG, Oduola AMJ, et al. In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria. Acta Trop. 2011;120:224–30. · DOI
  42. Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai–Myanmar Border (2003–2013): the role of parasite genetic factors. Clin Infect Dis. 2016;63:784. · DOI · Paper page
  43. Plucinski MM, Talundzic E, Morton L, Dimbu PR, Macaia AP, Fortes F, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, Angola. Antimicrob Agents Chemother. 2015;59:437–43. · DOI
  44. Ljolje D, Dimbu PR, Kelley J, Goldman I, Nace D, Macaia A, et al. Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015. Malar J. 2018;17:84. · DOI
  45. Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, Félix J, et al. Efficacy and safety of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar J. 2018;17:144. · DOI
  46. Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88. · DOI
  47. Schmedes SE, Patel D, Dhal S, Kelley J, Svigel SS, Dimbu PR, et al. Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014–2018. Emerg Infect Dis. 2021;27:1902. · DOI
  48. Dimbu PR, Horth R, Cândido ALM, Ferreira CM, Caquece F, Garcia LEA, et al. Continued low efficacy of artemether-lumefantrine in Angola in 2019. Antimicrob Agents Chemother. 2021;65:e01949-e2020. · doi:10.1128/aac.01949-20
  49. Dentinger CM, Rakotomanga TA, Rakotondrandriana A, Rakotoarisoa A, Rason MA, Moriarty LF, et al. Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018. Malar J. 2021;20:432. · doi:10.1186/s12936-021-03935-4
  50. Chidimatembue A, Svigel SS, Mayor A, Aíde P, Nhama A, Nhamussua L, et al. Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018. Malar J. 2021;20:398. · doi:10.1186/s12936-021-03930-9
  51. Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120–8. · DOI · Paper page
  52. Sidhu ABS, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol. 2005;57:913–26. · DOI
  53. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann A-C, et al. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun. 2016;7:11553. · DOI · Paper page
  54. Watson OJ, Gao B, Nguyen TD, Tran TN-A, Penny MA, Smith DL, et al. Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study. Lancet Microbe. 2022;3:e701–10. · DOI
  55. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163–71. · DOI · Paper page
  56. Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, et al. Evidence of artemisinin partial resistance in North-western Tanzania: clinical and drug resistance markers study. medRxiv. 2024. https://doi.org/10.1101/2024.01.31.24301954v1. · doi:10.1101/2024.01.31.24301954v1
  57. Boni MF, White NJ, Baird JK. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLoS Med. 2016;13: e1001984. · DOI
  58. Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HDT, Nguon C, et al. Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect Dis. 2022;22:867–78. · DOI
  59. Boni MF. Breaking the cycle of malaria treatment failure. Front Epidemiol. 2022;2:1041896. · DOI

Cited by

See all 13

Metadata

Authors
Laird, V. R., Plucinski, M. M., Venkatesan, M., Rondini, K. A., Randrianarivelojosia, M., Andriamananjara, M. N., Moonga, H., Ishengoma, D. S., Chidimatembue, A., Dimbu, P. R., Adeothy, A.-L., Beavogui, A. H., Kariuki, S., Nsobya, S. L., Uwimana, A., Kahunu, G. M., Assefa, A., Koita, O. A., Lucchi, N. W., Souza, S. S. S., Zhou, Z., Moriarty, L. F., & Halsey, E. S.
Venue
Malaria Journal
Published
2025-06-12
Volume
24
Issue
1
ISSN
1475-2875
Cited by
13
References
2
Language
en
Licence
Funders
United States President's Malaria Initiative

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatment. https://app.cochat.ai/papers/10.1186/s12936-025-05248-2
The paper
Laird, V. R., Plucinski, M. M., Venkatesan, M., Rondini, K. A., Randrianarivelojosia, M., Andriamananjara, M. N., Moonga, H., Ishengoma, D. S., Chidimatembue, A., Dimbu, P. R., Adeothy, A.-L., Beavogui, A. H., Kariuki, S., Nsobya, S. L., Uwimana, A., Kahunu, G. M., Assefa, A., Koita, O. A., Lucchi, N. W., . . . Halsey, E. S. (2025). Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatment. Malaria Journal. https://doi.org/10.1186/s12936-025-05248-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.